Cotrimazol en un sistema terapeutico rectal

En la presente Tesis se estudiaron experimentalmente las condiciones optimas para la administracion rectal de Trimetoprim con Sulfonamidas. El Trimetoprim se comparo con el Lactato de Trimetoprim. Entre las sulfamidas se ensayaron: Sulfametoxazol, Sulfamoxol, Sulfadiazina y Sulfameracina: tambien se emplearon sus sales sodicas. Se realizaron ensayos farmacotecnicos para seleccionar las mejoras formulaciones, profundizando en los ensayos de cesion "in vitro" a traves de membrana de celulosa. En algunas de las formulaciones seleccionadas se realizaron ensayos de biodisponibilidad relativa por excrecion urinaria en un total de ocho voluntarios, comprando la administracion oral y recta

Análisis de los modelos de familia desde la decada del 70 hasta el 2000 contenidos en la publicidad televisiva de cremas dentales: marca Colgate

Trabajo de grado (Publicista)-- Universidad Autónoma de Occidente, 2009PregradoPublicist

Prevalencia de hipotiroidismo y relación con niveles elevados de anticuerpos antiperoxidasa y yoduria en población de 35 y más años en armenia. 2009-2010

Objetivos Determinar la frecuencia de hipotiroidismo y su relación con anticuerpos antiperoxidasa  y yoduria elevada, con la finalidad de realizar recomendaciones a las autoridades sanitarias sobre el consumo de sal yodada y detección temprana de enfermedad tiroidea.Métodos Participaron 437 personas de la población general de Armenia (Quindío). Se realizaron pruebas ELISA para Tiroxina-L, hormona estimulante de la tiroides, anticuerpos antiperoxidasa y análisis fotocolorimétrico para yoduria. Resultados La prevalencia de hipotiroidismo fue de 18,5 %. Los anticuerpos antiperoxidasa fueron positivos en el 28,9 %, con prevalencia significativamente más alta entre aquellos con hormona estimulante de la tiroides mayor a 10 uUI/ml comparados con valores de 5,1 a 10 uUI/ml (O.R 3,2) y en fumadores (O.R 3,4). La Tiroxina-L fue normal en el 98,2 % de participantes con hormona estimulante de la tiroides mayor a 5 uUI/ml y en el 92 % de aquellos con valores mayores a 10 uUI/ml. El promedio de yoduria fue de 565,1; niveles por encima de 300 µg/l se obtuvieron en un 81,8 % de los participantes. Conclusiones El aumento en la prevalencia de anticuerpos antiperoxidasa positivo a medida que aumentan los valores de hormona estimulante de la tiroides podría evidenciar una elevado riesgo en Armenia de desarrollo de hipotiroidismo de origen autoinmune; a pesar de los elevados niveles de yoduria, no se logró establecer  relación con los niveles de anticuerpos antiperoxidasa ni de hormona estimulante de la tiroides

Predictores de mortalidad en pacientes con enfermedad pulmonar obstructiva crónica en Colombia: Un estudio de casos y controles

Objective. The objective of the study was to explore predictive variables of mortality in patients with COPD in Colombia. Materials and methods. Case-control study, in adult patients, diagnosed with COPD, treated at the clínica Comfamiliar, Risaralda, from January 1, 2015 to December 31, 2018. Deceased patients were called cases, and the control group was survivors. A data collection instrument validated by expert judgement was used. A multivariate logistic regression analysis was performed, followed by post-modeling analysis for validation. The analyzes were carried out in Stata 14, official version. It was considered significant with p value <0.05. The project was approved by the bioethics committee of the clínica Comfamiliar. Results. 230 patients with a diagnosis of COPD were included. The mortality rate was 10%, for which there were 23 cases. In the multivariate analysis, the predictors of mortality were Chronic Kidney Disease (CKD) (OR: 8.2, CI: 2.3-29.2, p = 0.001), presence of severe exacerbation in the last year (OR: 7.4, CI: 2.6-20.8, p <0.001), and hemoglobin in adequate ranges (Hb>12 in women/hb>13 in men) (OR: 0.82, CI: 0.68-0.99, p = 0.047). Conclusions. It was observed that CKD, severe exacerbations in the last year, and low hemoglobin values predict mortality in COPD patients in Colombia.Objetivo. El objetivo del estudio fue explorar variables predictivas de mortalidad en pacientes con EPOC de Colombia. Materiales y métodos. Estudio de casos y controles, en pacientes mayores de edad, con diagnóstico de EPOC, atendidos en la clínica “Comfamiliar”, Risaralda, del 1 de enero de 2015 a 31 de diciembre de 2018. Se denominó caso a pacientes fallecidos y el grupo control fueron los supervivientes. Se utilizó un instrumento de recolección de datos validado por juicio de expertos. Se realizó un análisis multivariado de tipo regresión logística y posteriormente análisis post modelamiento para su validación. Los análisis fueron realizados en Stata 14, versión oficial. Se considero significativo con p valor <0,05. El proyecto fue aprobado por el comité de bioética de la clínica Comfamiliar. Resultados. Se incluyeron 230 pacientes con diagnóstico de EPOC. La tasa de mortalidad fue de 10%, por lo que se contó con 23 casos. En el análisis multivariado, los factores predictores de mortalidad fueron la Enfermedad Renal Crónica (ERC) (OR: 8,2, IC: 2,3-29,2, p = 0,001), presencia de exacerbación severa el último año (OR: 7,4, IC: 2,6-20,8, p < 0,001), y la hemoglobina en rangos adecuados (Hb>12 in mujeres/hb>13 in hombres) (OR: 0,82, IC: 0,68-0,99, p = 0,047). Conclusiones. Se observó que la ERC, exacerbaciones severas el último año y valores bajos de hemoglobina predicen la mortalidad en el paciente con EPOC en Colombia

Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

[Objectives] To evaluate the efficacy and safety of the two-pill regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat as a switching strategy in heavily treatment-experienced people living with HIV (PLWH).[Methods] Multicentre, prospective, single-arm pilot clinical trial. Participants were virologically suppressed adults receiving a stable antiretroviral regimen of at least three pills from at least three drug families due to previous virological failures and/or toxicities with no documented resistance to integrase strand transfer inhibitors or darunavir (≥15 points, Stanford). Clinical and laboratory assessments were performed at 0, 4, 12, 24, 36 and 48 weeks. HIV-1 proviral DNA was amplified and sequenced by Illumina at baseline. Plasma bictegravir concentrations were determined in 22 patients using UHPLC-MS/MS. The primary study endpoint was viral load (VL)< 50 copies/mL at Week 48 (ITT).[Results] We enrolled 63 participants (92% men) with median baseline CD4 count of 515 cells/mm3 (IQR: 334.5–734.5), 24 years on ART (IQR: 15.9–27.8). The median number of pills was 4 (range: 3–10). At baseline, proviral DNA was amplified in 39 participants: 33/39 had resistance mutations. Three participants discontinued owing to toxicity. At 48 weeks, 95% had VL < 50 copies/mL by ITT and 100% by PP analysis. A modest increase was observed in the bictegravir plasma concentration, and a significant decrease in estimated glomerular filtration rate was observed only at Week 4, probably related to interaction with renal transporters.[Conclusions] Our data suggest that BIC/FTC/TAF + darunavir/cobicistat is an effective, well-tolerated regimen that may improve convenience and, potentially, long-term success in stable heavily pre-treated PLWH.This work was financed by Gilead Sciences, sponsored by the Spanish AIDS Research Network, and supported the by Fight Infections Foundation.Peer reviewe

Natural History of MYH7-Related Dilated Cardiomyopathy

BACKGROUND Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to 5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described. OBJECTIVES We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression. METHODS We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% female; 35.6 +/- 19.2 years) recruited from 29 international centers. RESULTS At initial evaluation, 106 (72.1%) patients had DCM (left ventricular ejection fraction: 34.5% +/- 11.7%). Median follow-up was 4.5 years (IQR: 1.7-8.0 years), and 23.7% of carriers who were initially phenotype-negative developed DCM. Phenotypic expression by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years of age. Thirty-six percent of patients with DCM met imaging criteria for LV noncompaction. During follow-up, 28% showed left ventricular reverse remodeling. Incidence of adverse cardiac events among patients with DCM at 5 years was 11.6%, with 5 (4.6%) deaths caused by end-stage heart failure (ESHF) and 5 patients (4.6%) requiring heart transplantation. The major ventricular arrhythmia rate was low (1.0% and 2.1% at 5 years in patients with DCM and in those with LVEF of <= 35%, respectively). ESHF and major ventricular arrhythmia were significantly lower compared with LMNA-related DCM and similar to DCM caused by TTN truncating variants. CONCLUSIONS MYH7-related DCM is characterized by early age of onset, high phenotypic expression, low left ventricular reverse remodeling, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, which are rare. (C) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Muon reconstruction performance of the ATLAS detector in proton–proton collision data at √s = 13 TeV

This article documents the performance of the ATLAS muon identification and reconstruction using the LHC dataset recorded at √s = 13 TeV in 2015. Using a large sample of J/ψ→μμ and Z→μμ decays from 3.2 fb−1 of pp collision data, measurements of the reconstruction efficiency, as well as of the momentum scale and resolution, are presented and compared to Monte Carlo simulations. The reconstruction efficiency is measured to be close to 99% over most of the covered phase space (|η| 2.2, the pT resolution for muons from Z→μμ decays is 2.9 % while the precision of the momentum scale for low-pT muons from J/ψ→μμ decays is about 0.2%

Constraints on new phenomena via Higgs boson couplings and invisible decays with the ATLAS detector

Abstract: The ATLAS experiment at the LHC has measured the Higgs boson couplings and mass, and searched for invisible Higgs boson decays, using multiple production and decay channels with up to 4.7 fb−1 of pp collision data at−1at TeV. In the current study, the measured production and decay rates of the observed Higgs boson in the γγ, ZZ, W W , Zγ, bb, τ τ , and μμ decay channels, along with results from the associated production of a Higgs boson with a top-quark pair, are used to probe the scaling of the couplings with mass. Limits are set on parameters in extensions of the Standard Model including a composite Higgs boson, an additional electroweak singlet, and two-Higgs-doublet models. Together with the measured mass of the scalar Higgs boson in the γγ and ZZ decay modes, a lower limit is set on the pseudoscalar Higgs boson mass of mA&gt; 370 GeV in the “hMSSM” simplified Minimal Supersymmetric Standard Model. Results from direct searches for heavy Higgs bosons are also interpreted in the hMSSM. Direct searches for invisible Higgs boson decays in the vector-boson fusion and associated production of a Higgs boson with W/Z (Z → ℓℓ, W/Z → jj) modes are statistically combined to set an upper limit on the Higgs boson invisible branching ratio of 0.25. The use of the measured visible decay rates in a more general coupling fit improves the upper limit to 0.23, constraining a Higgs portal model of dark matter.[Figure not available: see fulltext.

Search for pair and single production of new heavy quarks that decay to a Z boson and a third-generation quark in pp collisions at √s = 8TeV with the ATLAS detector

A search is presented for the production of new heavy quarks that decay to a Z boson and a third-generation Standard Model quark. In the case of a new charge +2/3 quark (T), the decay targeted is T -&gt; Zt, while the decay targeted for a new charge -1/3 quark (B) is B -&gt; Zb. The search is performed with a dataset corresponding to 20.3 fb(-1) of p p collisions at root s = 8TeV recorded in 2012 with the ATLAS detector at the CERN Large Hadron Collider. Selected events contain a high transverse momentum Z boson candidate reconstructed from a pair of oppositely charged same-flavor leptons (electrons or muons), and are analyzed in two channels defined by the absence or presence of a third lepton. Hadronic jets, in particular those with properties consistent with the decay of a b-hadron, are also required to be present in selected events. Different requirements are made on the jet activity in the event in order to enhance the sensitivity to either heavy quark pair production mediated by the strong interaction, or single production mediated by the electroweak interaction. No significant excess of events above the Standard Model expectation is observed, and lower limits are derived on the mass of vector-like T and B quarks under various branching ratio hypotheses, as well as upper limits on the magnitude of electroweak coupling parameters